IP Library › Granted Patent US 10,131,704
Granted Patent B2
US 10,131,704 · App. 15/306,617 · Granted Nov 20, 2018

Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof

Inventors: Wayne A. Marasco (Wellesley, MA); Xiangchun Tang (West Roxbury, MA)
Assignee: DANA-FARBER CANCER INSTITUTE, INC.
C07K16/10G01N33/56983G01N33/577A61K2039/507C07K2317/13C07K2317/21C07K2317/34C07K2317/52C07K2317/56C07K2317/622C07K2317/76C07K2317/92C07K2319/40C07K2319/43C12N2740/16043C12N2770/20022C12N2810/609G01N2333/165G01N2469/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,131,704
App. No.
15/306,617
Granted
Nov 20, 2018
Kind
B2
Abstract

The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.

Claims (19)

1. An isolated monoclonal antibody, wherein said monoclonal antibody binds to an epitope in the receptor binding domain (RBD) of the spike protein of a Middle East Respiratory Syndrome coronavirus (MERS-CoV), and neutralizes MERS-CoV, and wherein the monoclonal antibody comprises a V H amino acid sequence having SEQ ID NO: 14, and a V L amino acid sequence having SEQ ID NO: 16.

2. The monoclonal antibody of claim 1 , wherein said epitope is non-linear.

3. The monoclonal antibody of claim 1 , wherein said epitope comprises a region within amino acids 349-590 of the spike protein when numbered in accordance with SEQ ID NO: 58.

4. The monoclonal antibody of claim 1 , wherein the epitope comprises at least one amino acid at position 506, 512, 540, 542 or 547 of the spike protein when numbered in accordance with SEQ ID NO: 58.

5. The monoclonal antibody of claim 1 , wherein said monoclonal antibody inhibits viral and cell membrane fusion.

6. The monoclonal antibody of claim 1 , wherein said monoclonal antibody competes with the binding of monoclonal antibody 1E9, 1F8, 3B12, 3A1, 3C12, 3B11 or M14D3 to the spike protein.

7. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is a fully human antibody.

8. The monoclonal antibody of claim 1 , wherein said monoclonal antibody blocks the binding of MERS-CoV spike protein to DPP4 receptor.

9. The monoclonal antibody of claim 1 , wherein said monoclonal antibody is produced in a plant.

10. An isolated scFv antibody, wherein said antibody binds to an epitope in the receptor binding domain (RBD) of the spike protein of a Middle East Respiratory Syndrome coronavirus (MERS-CoV), and neutralizes MERS-CoV, and wherein the isolated scFv antibody comprises a V H amino acid sequence having SEQ ID NO: 14, and a V L amino acid sequence having SEQ ID NO: 16.

11. The scFv antibody of claim 10 , wherein said epitope is non-linear.

12. The scFv antibody of claim 10 , wherein said epitope comprises a region within amino acids 349-590 of the spike protein when numbered in accordance with SEQ ID NO: 58.

13. The scFv antibody of claim 10 , wherein the epitope comprises at least one amino acid at position 506, 512, 540, 542 or 547 of the spike protein when numbered in accordance with SEQ ID NO: 58.

14. The scFv antibody of claim 10 , wherein said scFv antibody inhibits viral and cell membrane fusion.

15. The scFv antibody of claim 10 , wherein said scFv antibody competes with the binding of monoclonal antibody 1E9, 1F8, 3B12, 3A1, 3C12, 3B11 or M14D3 to the spike protein.

16. The scFv antibody of claim 10 , wherein said monoclonal antibody blocks the binding of MERS-CoV spike protein to DPP4 receptor.

17. A composition comprising the monoclonal antibody of claim 1 and a carrier.

18. An isolated monoclonal antibody, wherein said monoclonal antibody binds to an epitope in the receptor binding domain (RBD) of the spike protein of a Middle East Respiratory Syndrome coronavirus (MERS-CoV), and neutralizes MERS-CoV, and wherein said monoclonal antibody comprises a heavy chain with three CDRs comprising the amino acid sequences GGTFSSYA (SEQ ID NO:35), IIPIFGTA (SEQ ID NO:38), and ARVGYCSSTSCHIGAFDI (SEQ ID NO:39) respectively and a light chain with three CDRs comprising the amino acid sequences QSVSSS (SEQ ID NO:55), DSS (SEQ ID NO:56), and QQYSSSPYT (SEQ ID NO:57) respectively.

19. An isolated scFv antibody, wherein said antibody binds to an epitope in the receptor binding domain (RBD) of the spike protein of a Middle East Respiratory Syndrome coronavirus (MERS-CoV), and neutralizes MERS-CoV, wherein said scFv antibody comprises a heavy chain with three CDRs comprising the amino acid sequences GGTFSSYA (SEQ ID NO:35), IIPIFGTA (SEQ ID NO:38), and ARVGYCSSTSCHIGAFDI (SEQ ID NO:39) respectively and a light chain with three CDRs comprising the amino acid sequences QSVSSS (SEQ ID NO:55), DSS (SEQ ID NO:56), and QQYSSSPYT (SEQ ID NO:57) respectively.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2017
From: TANG, XIANCHUN
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 042130/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: MARASCO, WAYNE A.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 041347/0479 →
CONFIRMATORY LICENSE Recorded Jan 19, 2017
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041430/0851 →
Continuity (2)
Provisional Application 61984243 · Apr 25, 2014
Related Publication 20170158752A1 · Jun 8, 2017
Cited By (1)
US 12,312,409